"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325561.
-
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial). Sci Rep. 2025 Mar 22; 15(1):9882.
-
Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques. Gene Ther. 2025 Jan; 32(1):16-24.
-
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. J Infect Dis. 2024 03 14; 229(3):671-679.
-
Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs. Cell Rep Methods. 2022 03 28; 2(3):100181.
-
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis. 2022 05; 22(5):636-648.
-
Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis. 2014 May 15; 209(10):1573-84.
-
Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure. 2012 Feb 08; 20(2):303-14.
-
Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-? agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol. 2011 Jul; 301(1):L125-34.